Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT02570126
Other study ID # 200147
Secondary ID 2013-003535-30
Status Completed
Phase Phase 3
First received
Last updated
Start date November 13, 2015
Est. completion date October 25, 2016

Study information

Verified date November 2019
Source GlaxoSmithKline
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The purpose of this study is to evaluate the safety and immunogenicity of 2 formulations of GSK Biologicals' varicella vaccines given as a 2-dose course in the second year of life.


Description:

GSK Biologicals has removed human serum albumin (a stabilizer) from its varicella vaccine to minimize as much as possible the use of animal or human-derived products in the production of vaccines. The study is intended to provide information on the safety and immunogenicity of GlaxoSmithKline (GSK) Biologicals' candidate varicella vaccine formulated without human serum albumin (HSA) in contrast to Varilrix™ (GSK) which contains HSA when both are used in a two-dose schedule, with the first and second doses given approximately 42 days apart in the second year of life.

The immunogenicity sub-cohort will be comprised of approximately 400 subjects, representing approximately 100 subjects enrolled in each of the participating countries.

Rationale for amendment 1: Sites in the UK can perform home visits. For subjects participating through home visits, the subject's parent(s) / Legally Acceptable Representative(s) [LAR(s)] will be requested to sign a Recruitment/Randomisation agreement to provide personal information and to agree to have their child randomised before providing written consent to participate in the study (to be provided at the 1st home visit).


Recruitment information / eligibility

Status Completed
Enrollment 1236
Est. completion date October 25, 2016
Est. primary completion date October 25, 2016
Accepts healthy volunteers Accepts Healthy Volunteers
Gender All
Age group 12 Months to 23 Months
Eligibility Inclusion Criteria:

- Subjects' parent(s)/ LAR(s) who, in the opinion of the investigator, can and will comply with the requirements of the protocol.

- A male or female between, and including, 12 and 23 months of age (i.e. 12 months to a day before 24 months) at the time of the first study vaccination.

- Written informed consent obtained from the parent(s)/LAR(s) of the subject prior to performing any study specific procedure.

- Subjects in stable health as determined by investigator's clinical examination and assessment of subject's medical history.

- Subjects must have had prior administration of a dose of measles, mumps and rubella (MMR) vaccine at least 30 days (Day -31 or earlier) prior to study vaccination at Day 0.

Exclusion Criteria:

- Child in care.

- Use of any investigational or non-registered product other than the study vaccines during the period starting 30 days before the day of study vaccination (i.e., 30 days prior to Visit 1/Day 0) or planned use during the entire study period.

- Concurrently participating in another clinical study, in which the child has been or will be exposed to an investigational or a non-investigational product.

- Chronic administration (defined as 14 or more consecutive days) of immunosuppressants, or other immune-modifying drugs during the period starting 180 days prior to the first vaccine dose or any planned administration of immunosuppressive and immune-modifying drugs during the entire study.

- For corticosteroids, this will mean prednisone =0.5 mg/kg/day or equivalent.

- Inhaled and topical steroids are allowed.

- Planned administration/ administration of a live viral vaccine not foreseen by the study protocol during the period starting 30 days prior to study vaccination at Visit 1/Day 0 until study end. Non study live viral vaccines can be administered at Visit 3 (Day 84) after completion of study procedures.

- Planned administration/ administration of an inactivated vaccine not foreseen by the study protocol during the period starting 7 days prior to each vaccination (at Visit 1/Day 0 and Visit 2/Day 42) and ending 14 days after each vaccination. Outside of this period, non-study inactivated vaccines can be administered as per standard of care.

- Administration of immunoglobulins and/or any blood products during the period starting 180 days prior to the first vaccine dose or planned administration from the date of first study vaccination through the entire study.

- History of varicella or zoster.

- Known exposure to varicella/zoster during the period starting within 30 days prior to first study vaccination.

- Previous vaccination against varicella.

- Any confirmed or suspected immunosuppressive or immunodeficient condition, based on medical history and physical examination (no laboratory testing required).

- Subjects with blood dyscrasias, leukemia, and lymphomas of any type.

- A family history of congenital or hereditary immunodeficiency

- History of allergic disease or reactions likely to be exacerbated by any component of the vaccines, including hypersensitivity to neomycin or latex.

- Major congenital defects or serious chronic illness.

- Acute disease and/or fever at the time of enrolment.

- Fever is defined as temperature =38. 0°C/100.4°F by any age appropriate route.

- Subjects with a minor illness without fever may be enrolled at the discretion of the investigator.

- Active untreated tuberculosis based on medical history.

- Any other condition which, in the opinion of the investigator, prevents the child from participating in the study.

Study Design


Related Conditions & MeSH terms


Intervention

Biological:
Varilrix HSA-free
2 doses will be administered, one at Day 0 and the other at Day 42
Varilrix™
2 doses will be administered, one at Day 0 and the other at Day 42

Locations

Country Name City State
Estonia GSK Investigational Site Tallinn
Estonia GSK Investigational Site Tallinn
Estonia GSK Investigational Site Tartu
Germany GSK Investigational Site Aschaffenburg Bayern
Germany GSK Investigational Site Berlin
Germany GSK Investigational Site Detmold Nordrhein-Westfalen
Germany GSK Investigational Site Frankenthal Rheinland-Pfalz
Germany GSK Investigational Site Kehl Baden-Wuerttemberg
Germany GSK Investigational Site Neumuenster
Germany GSK Investigational Site Schoenau Am Koenigssee Bayern
Germany GSK Investigational Site Solingen Nordrhein-Westfalen
Germany GSK Investigational Site Stuttgart Baden-Wuerttemberg
Germany GSK Investigational Site Stuttgart Baden-Wuerttemberg
Germany GSK Investigational Site Tauberbischofsheim Baden-Wuerttemberg
Germany GSK Investigational Site Vellmar Hessen
Germany GSK Investigational Site Wurzen Sachsen
Mexico GSK Investigational Site Merida Yucatán
Mexico GSK Investigational Site Mexico city
Thailand GSK Investigational Site Bangkok
United Kingdom GSK Investigational Site Bristol
United Kingdom GSK Investigational Site London
United Kingdom GSK Investigational Site Oxford
United Kingdom GSK Investigational Site Southampton

Sponsors (1)

Lead Sponsor Collaborator
GlaxoSmithKline

Countries where clinical trial is conducted

Estonia,  Germany,  Mexico,  Thailand,  United Kingdom, 

References & Publications (1)

Faust SN, Le Roy M, Pancharoen C, Weber MAR, Cathie K, Behre U, Bernatoniene J, Snape MD, Helm K, Medina Pech CE, Henry O, Baccarini C, Povey M, Gillard P. Safety and immunogenicity of a varicella vaccine without human serum albumin (HSA) versus a HSA-containing formulation administered in the second year of life: a phase III, double-blind, randomized study. BMC Pediatr. 2019 Feb 7;19(1):50. doi: 10.1186/s12887-019-1425-7. — View Citation

Outcome

Type Measure Description Time frame Safety issue
Primary Number of Subjects Reporting Fever Fever was defined as axillary temperature above (>) 39.0 °C (> 102.2°F) 15-days (Days 0-14) post Dose 1 of varicella vaccination
Secondary Number of Subjects Reporting Fever Fever was defined as axillary temperature greater than or equal to (=) 38.0°C (= 100.4°F) 15 days post each dose of varicella vaccination
Secondary Evaluation of Immune Response to Varicella Vaccine With Respect to Anti Varicella Zoster Virus (Anti-VZV) Antibody Concentrations (Immuno-sub Cohort) Anti-VZY antibody concentrations were expressed in terms of Geometric Mean Concentrations (GMCs) At Day 42 and Day 84 post vaccination
Secondary Number of Subjects With a Seroresponse to VZV (Immuno Sub Cohort) For VZV, seroresponse was defined as, post-vaccination anti-VZV antibody concentration = 50 mIU/mL among subjects who were seronegative (antibody concentration below (< ) 25 mIU/mL) before vaccination At Day 42 and Day 84 post vaccination
Secondary Number of Subjects Reporting Solicited Local Symptoms Solicited local symptoms assessed were pain, injection site redness and swelling. Any = occurrence of the specified solicited local symptom regardless of its intensity. Grade 3 pain = subject crying when limb was moved or as spontaneously painful. Grade 3 redness and swelling = above (>) 20 mm 4-day post vaccination period following Dose 1 (Day 0) and Dose 2 (Day 42)
Secondary Number of Subjects Reporting Fever Any fever (= 38°C) = occurrence of any fever regardless of its intensity grade or relationship to vaccination. Grade 3 fever = temperature > 39.5°C. Related fever = assessed by the investigator as causally related to study vaccination 43-day post vaccination period following Dose 1 (Day 0) and Dose 2 (Day 42)
Secondary Number of Subjects Reporting Rash Any rash = occurrence of the specified solicited general symptom regardless of its intensity. Grade 3 rash = rash which prevented normal, everyday activities. Related rash = assessed by the investigator as causally related to study vaccination 43-day post vaccination period following Dose 1 (Day 0) and Dose 2 (Day 42)
Secondary Number of Subjects Reporting Febrile Convulsions Any febrile convulsion = occurrence of the specified solicited general symptom regardless of its intensity. Grade 3 febrile convulsion = febrile convulsion which prevented normal, everyday activities. Related febrile convulsion = assessed by the investigator as causally related to study vaccination 43-day post vaccination period following Dose 1 (Day 0) and Dose 2 (Day 42)
Secondary Number of Subjects Reporting Unsolicited Adverse Events (AEs) Unsolicited AE covers any AE reported in addition to those solicited during the clinical study and any solicited symptom with onset outside the specified period of follow-up for solicited symptoms. Any = occurrence of any unsolicited symptom regardless of intensity grade or relation to vaccination 43-day post vaccination period following Dose 1 (Day 0) and Dose 2 (Day 42)
Secondary Number of Subjects Reporting Serious Adverse Events (SAEs) SAEs assessed included medical occurrences that resulted in death, were life threatening, required hospitalisation or prolongation of hospitalisation or resulted in disability/incapacity. Any SAE = occurrence of SAE regardless of intensity grade or relation to vaccination From Day 0 through the end of study (Day 84)
See also
  Status Clinical Trial Phase
Completed NCT01887496 - Varicella-related Hospitalizations in Turkey N/A
Completed NCT00326183 - Hepatitis A Vaccine, Inactivated and Measles, Mumps, Rubella and Varicella Virus Vaccine Live Safety Study (V251-066)(COMPLETED) Phase 4
Completed NCT02452229 - Review of Human Herpes Viruses in Burns N/A
Completed NCT01815073 - Immunogenicity and Safety of Live Attenuated Varicella Vaccine Combined With Live Attenuated JE Vaccine Phase 4
Completed NCT01817270 - Immunogenicity and Safety Study of 2 Doses of Live Attenuated Varicella Vaccine Phase 4
Active, not recruiting NCT01982409 - Immune Persistence After Inoculated With One-dose Freeze-Dried Live Attenuated Varicella Vaccine in Children Vaccine in Children Phase 4
Completed NCT00921999 - Immune Response to Varicella-Zoster Vaccination and Infection N/A
Completed NCT00098046 - Famciclovir Oral Pediatric Formulation in Children 1-12 Years of Age With Varicella Zoster Infection Phase 3
Completed NCT05732337 - Open Clinical Investigation to Evaluate the Effectiveness and Safety of a Topical Medical Device. N/A
Completed NCT01684072 - Safety and Immunogenicity Study of Live Attenuated Vaccine Against Varicella Without Gelatin Phase 4
Completed NCT00156559 - MMR and Varicella Vaccine in Premature Infants Phase 4
Active, not recruiting NCT05084508 - A Study on the Immune Response and Safety of Various Potencies of an Investigational Chickenpox Vaccine Compared With a Marketed Chickenpox Vaccine, Given to Healthy Children 12 to 15 Months of Age Phase 2
Completed NCT04384016 - Safety and Immunogenicity of Skyvaricella Injection in Healthy Volunteer Vietnamese Children From 12 Months to 12 Years Old Phase 4
Completed NCT00001125 - Use of a Varicella-Zoster Virus (VZV) Vaccine to Prevent Shingles in HIV-Infected Children Who Have Already Had Chickenpox Phase 1
Withdrawn NCT00001054 - The Safety and Effectiveness of Valacyclovir HCl in the Treatment of Herpes Simplex or Varicella/Zoster Infections in HIV-1 Infected Children Phase 1
Completed NCT00002358 - A Study of BV-araU in the Treatment of Varicella-Zoster Viral Disease (VZV) in HIV-Infected Children Who Have Not Had Success With or Who Cannot Take Other Treatments for VZV Phase 3
Completed NCT00002315 - A Comparison of 882C87 Versus Acyclovir in the Treatment of Herpes Zoster in Patients With Weakened Immune Systems Phase 3
Completed NCT00000953 - Comparison of Brovavir Versus Acyclovir in the Treatment of Herpes in HIV-Infected Patients Phase 2